L
eft ventricular hypertrophy (LVH) is a strong independent predictor of coronary events, 1, 2 and the link between LVH and myocardial ischemia remains an area of intense research. Many of these research studies require assessment of myocardial oxygen demand. Direct measurement of myocardial oxygen consumption by invasive techniques is not practical for routine application; thus, investigators use noninvasive surrogates for assessment of myocardial oxygen demand. However, the best surrogate for MVO 2 in patients with hypertension induced LVH is not known. The commonly used surrogates include double product (DP), triple product, and tension-time index. 3 These surrogates are limited by the fact that they do not take left ventricular (LV) size and myocardial contractility into consideration. Baller et al 4 in a canine model demonstrated that relationships between standard surrogates and directly measured MVO 2 became weaker as myocardial contractility increased. Lately, other noninvasive surrogates that incorporate either LV size or myocardial contractility are being used by investigators. These surrogates include peak systolic wall stress (PSS), 5 myocardial contractility assessed by echocardiographic mid-wall fractional shortening (MFS), and stress-massheart rate product (SMH). 6 However, relationships between these surrogates and directly measured MVO 2 in patients with hypertension induced LVH have not been adequately studied. Hence, the objectives of this study were to define the best correlate of MVO 2 among the following variables: heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), double product (DP), peak systolic stress (PSS), modified tension time index (mTTI), mid-wall fractional shortening (MFS), and SMH in patients with hypertension induced LVH. In addition we sought to examine whether relationships between these variables and resting MVO 2 differed between patients with hypertension induced LVH and normotensive control subjects.
Methods
The Institutional Review Board of Columbia University approved the study. Informed consent was obtained for each patient. Participants with pre-existing hypertension and LVH as well as normotensive control subjects were recruited from the patient population at New York Presbyterian Medical Center in New York City and the surrounding community. Pre-existing hypertension was validated by blood pressure (BP) measurement on entry.
Exclusion criteria for patients with hypertension and LVH included the following: echocardiographic evidence of significant cardiac abnormality other than hypertrophy, such as valvular heart disease, LV systolic dysfunction, and regional echocardiographic wall motion abnormalities suggestive of coronary artery disease; significant cardiovascular disease other than hypertension with LVH, diabetes mellitus, history of chest pain, and pregnancy. Additional exclusion criteria for normotensive control subjects included hypertension and LVH.
Using these criteria, we recruited 20 patients with hypertension induced LVH and 10 normotensive control subjects.
Measurement of Resting MVO 2 By Positron Emission Tomography Using Carbon-11 Acetate
To measure resting MVO 2 by positron emission tomography (PET) using carbon-11 ( 11 C) acetate, we used a PET scanner (model ECAT EXACT-47 PET, CTI Corp., Knoxville, TN), which provides 47 contiguous transaxial slices and has a postprocessing spatial resolution of 9 to 10 mm in plane and 4 to 5 mm in the axial direction. Subjects were studied after an overnight fast. They were placed supine in the PET scanner, and localization of the heart within the axial field of view of the scanner was confirmed by performing a 2-min "positioning" scan using a rotating 68 Ge/ 68 Ga-rod source. A 20-min transmission scan with the rotating 68 Ge/ 68 Ga -rod source was performed to generate an attenuation correction map for correction of the emission sinogram. Approximately 0.2 mCi/kg of 11 Cacetate was injected intravenously as a bolus. A 30-min dynamic data acquisition was performed using multiple frames with progressively increasing scan lengths (10-sec frames ϫ 12, 60-sec frames ϫ 5, 90-sec frames ϫ 10, and 120-sec frames ϫ 4). Emission sinograms were corrected for attenuation and radioactivity decay and reconstructed into transaxial slices. Transaxial slices were reoriented into six short axis slices using standard system software. Each short axis slice was divided into eight equal myocardial sectors, and count data in each sector used to generate myocardial time activity curves describing the clearance of 11 C activity from the myocardium. A monoexponential fit for the myocardial time activity curve of 11 C clearance was performed. The monoexponential myocardial turnover rate constant, kmono, which describes the clearance of 11 C activity from the myocardium, correlates closely with MVO 2 under resting conditions. Thus, rMVO 2 was determined from a regression equation that converts kmono (in units of min Ϫ1 ) to rMVO 2 (in units of mol/g/min)).
7-10 Variations in rMVO 2 were evaluated by calculating regional variance. Because there was no significant difference in regional variance, rMVO 2 was averaged MVO 2 to yield total MVO 2 for the entire ventricle.
Measurement of LV Mass
An LV mass of Ͼ125 g/m 2 by screening M-mode echocardiography was used as an inclusion criterion for patients and as an exclusion criterion for control subjects. 1 To minimize measurement variability, LV mass and volume were assessed by three-dimensional (3D) echocardiography.
The components, operation, and major features of the 3D echocardiography system developed at Columbia University have been previously described in detail. 14, 15 Briefly, the 3D echocardiography system (K3 Systems, Darien, CT) comprises an acoustic spatial locater (model GP 8-3D, Science Accessories Corp., Stratford, CT) and personal computer (model 4DX-33V, Gateway 2000, North Sioux City, SD). These components were linked to a conventional two-dimensional echocardiograph. Left ventricular volume was computed from a series of guided, 6 to 8 real-time parasternal short axis images. These images were stored along with their XYZ Cartesian coordinates in the personal computer. End-diastolic video frames from each acquired cine-loop were selected for off-line endocardial and epicardial boundary tracing in diastole. Epicardial and endocardial volumes were determined from their corresponding boundaries using a polyhedral surface reconstruction algorithm. Endocardial volume (EDV) was subtracted from epicardial volume to yield myocardial volume, which was multiplied by myocardial density to yield myocardial mass.
Measurement of LV Wall Stress
Left ventricular peak-systolic stress was calculated using the following formula: (0.334 * SBP * LVDd)/LVPWT * (1ϩ LVPWT/LVDd), 11 where LVDd ϭ LV diameter at end-diastole, and LVPWT ϭ LV posterior wall thickness.
Measurement of Myocardial Contractility
Myocardial contractility in patients was assessed by calculating MFS (%) using the following formula: 12 [LVDd ϩ LVPWT/2ϩLVAWT/2) Ϫ (LVDs ϩ inner shell myocardial thickness)]/(LVDdϩLVPWT/2ϩLVAWT/2)ϫ100, where LVAWT ϭ LV anterior wall thickness, and LVDs ϭ LV diameter at end-systole, with inner shell myocardial thickness computed as
ϪLVDs. Myocardial contractility in control subjects was assessed by calculating LV fractional shortening using the following formula: (LVDdϪLVDs)/ LVDd.
Modified Tension-Time Index
This parameter was calculated by multiplying the mean arterial pressure by the square root of heart rate. 13 
Statistical Methods
All values were expressed as mean Ϯ SD. Correlates of MVO 2 on univariate and multivariate analysis were determined by linear regression analyses. A probability value of P Ͻ .05 was considered to be statistically significant.
Results

Population Characteristics
There was no significant difference between patients and control subjects in terms of age and sex. The average duration of hypertension in patients was 5 years ( Table 1) . As expected, patients exhibited significantly higher BP and LV mass measurements (P Ͻ . 005) ( Table 1) . Patients also had significantly higher mean values for DP, mTTI, SMH, and total MVO 2 . There was no difference in PSS values between patients and control subjects (Table  1) .
Correlation With MVO 2
Mean total MVO 2 was significantly higher in patients than in control subjects: 23 Ϯ 5 mL/min v 13 Ϯ 3 mL/min (P ϭ 0.004) ( Table 1) . However, MVO 2 /g was not different between patients and control subjects 0.12 v 0.11 mL/g/ min (P ϭ ns). Mean values for tested variables are given in Table 1 . By univariate analysis, the variables that correlated with total MVO 2 in the patients were HR (r ϭ 0.65, P ϭ .002, MVO 2 ϭ 0.46 ϩ 0.07 * HR), SMH (r ϭ 0.63, P ϭ .003, MVO 2 ϭ 3.62 ϩ 0.0000008 * SMH), DP (r ϭ 0.63, P ϭ .003, MVO 2 ϭ 2.89 ϩ 0.0002 * DP), mTTI (r ϭ 0.55, P ϭ .01, MVO 2 ϭ 0.48 ϩ 0.0047 * MVO 2 ), and PSS (r ϭ 0.54, P ϭ .0, MVO 2 ϭ 3.75 ϩ 0.009 * PSS). In the control subjects, the significant correlates of total MVO 2 were HR (r ϭ 0.68, P ϭ .03, MVO 2 ϭ1.02 ϩ 0.06 * HR), SMH (r ϭ 0.73, P ϭ .02, MVO 2 ϭ 3.82 ϩ 0.0000008 * SMH), DP (r ϭ 0.64, P ϭ .04, MVO 2 ϭ 3.00 ϩ 0.0003 * DP), PSS (r ϭ 0.69, P ϭ .03, MVO 2 ϭ 3.81 ϩ 0.007 * PSS) and DBP (r ϭ 0.64, P ϭ .04, MVO 2 ϭ3.00 ϩ 0.0003 * DBP). In the combined group of patients and control subjects, variables that correlated with total MVO 2 were HR (r ϭ 0.65, P ϭ .0009, MVO 2 ϭ 0.46 ϩ 0.07 * HR), SMH (r ϭ 0.64, P ϭ .0001, MVO 2 ϭ 3.62 ϩ 0.0000008 * SMH), DP (r ϭ 056, P ϭ .001, MVO 2 ϭ 2.89 ϩ 0.0002 * DP), PSS (r ϭ 0.46, P ϭ .01, MVO 2 ϭ 3.75 ϩ 0.009 * PSS) and mTTI (r ϭ 0.43, P ϭ .01, MVO 2 ϭ 0.51 ϩ 0.005 * TTI). On multivariate analysis, the single best determinant of total MVO 2 in the patients was SMH (r ϭ 0.67, P ϭ .001, MVO 2 ϭ 3.53 ϩ 0.000019 * SMH).
Discussion
On univariate analyses, the strongest correlates of MVO 2 were SMH in control subjects and SMH, HR, and DP in the patients. In the combined population, SMH and HR had the best correlation with MVO 2 . On multivariate analysis, the single best correlate of MVO 2 in the patients was SMH. The moderate correlation between the significant variables and MVO 2 could be attributable to the narrow range of resting MVO 2 values in our study. Although several studies have examined correlates of MVO 2 after pharmacologic stress or atrial pacing, ours is the first study to examine correlates of MVO 2 in patients with hypertension induced LVH under resting conditions. With the exception of diastolic BP and peak systolic stress, all of the significant variables are directly related to heart rate, which underscores the impact of the latter on resting MVO 2 . Several investigators have shown the relationships among heart rate, double product, and MVO 2 . However, the relationship between stressmass-heart rate product and MVO 2 has not been adequately studied. 4, 13 Because wall stress is directly related to volume/mass ratio and BP, stress-mass-heart rate product essentially incorporates ventricular volume, BP, and heart rate, which explain its relationship to MVO 2 . Although stress-mass-heart rate product, heart rate, and double product do not account for changes in myocardial contractility (which is a known determinant of MVO 2 ), they did correlate significantly with resting MVO 2 . This could be attributable to the narrow range of contractility values in the population. Furthermore, heart rate and double product do not account for changes in ventricular volume, a determinant of wall stress, however the range of ventricular volumes in the population is narrow because most of the patients had concentric hypertrophy.
With the exception of DBP, which correlated with MVO 2 in the control subjects but not in patients, there was no difference between patients and control subjects in the variables that correlated with MVO 2 .
The clinical implications of our findings underscore that heart rate is an important determinant of myocardial energy demand under resting conditions, and that SMH is the best correlate of resting MVO 2 in patients with hypertension induced LVH. Thus, patients with hypertension induced LVH who have angina would benefit from interventions that lower heart rate.
Some limitations of this study should be recognized. First, we studied all subjects under resting conditions; as a result, our findings may not be applicable to situations in which myocardial energy demands is increased. Second, we did not measure systolic ejection time; consequently, we could not calculate tension-time index or triple product. It is possible that these indices may yield better correlations with MVO 2 .
In conclusion, heart rate, stress-mass-heart rate product, double product, modified tension time index, and peak systolic stress correlate significantly with MVO 2 in patients with hypertension induced LVH. These same variables, along with diastolic BP, correlate significantly with MVO 2 in normotensive control subjects. The best correlate of MVO 2 in patients with hypertension induced LVH was stress-mass-heart rate product.
